Sacituzumab Tirumotecan

The antibody-drug conjugate (ADC) market in non-small-cell lung cancer is projected to grow at a 6.8% CAGR across seven major markets and exceed $3.9 billion by 2032.

Recent findings demonstrate that folate receptor-alpha expression levels strongly correlate with mirvetuximab soravtansine-gynx efficacy in ovarian cancer treatment, showing highest activity in patients with high expression.

Sacituzumab tirumotecan (sac-TMT) demonstrates antitumor activity in patients with pretreated advanced endometrial and ovarian cancers, offering a potential new treatment option.

Eli Lilly's Zepbound showed a 47% greater relative weight loss compared to Novo Nordisk’s Wegovy in a head-to-head obesity study.

Sacituzumab tirumotecan (sac-TMT) monotherapy shows promising antitumor activity in patients with previously treated advanced endometrial cancer, with an objective response rate (ORR) of 34.1%.